Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

IMPORTANCE: Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. OBJECTIVE: To evaluate the effects of dapagliflozin in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: Petrie, Mark C., Verma, Subodh, Docherty, Kieran F., Inzucchi, Silvio E., Anand, Inder, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K., de Boer, Rudolf A., Desai, Akshay S., Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andre, Ge, Junbo, Howlett, Jonathan, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E. A., Merkely, Béla, Nicolau, Jose C., O'Meara, Eileen, Vinh, Pham Nguyen, Schou, Morten, Tereshchenko, Sergey, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Johanson, Per, Greasley, Peter J., Boulton, David, Bengtsson, Olof, Jhund, Pardeep S., McMurray, John J. V.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7157181/
https://ncbi.nlm.nih.gov/pubmed/32219386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.1906
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados